Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer

Video

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses treatment options for patients with HER2-positive breast cancer.

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses treatment options for patients with HER2-positive breast cancer.

According to Hurvitz, the treatments for HER2-positive breast cancer have evolved over the past 5 years. There is now refined criteria for treatments that physicians should be giving in the first-line and second-line settings.

The standard of care for the first-line setting is trastuzumab (Herceptin) and pertuzumab (Perjecta) with a taxane to be given for 4 to 6 cycles, explains Hurvitz.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD